Oxford Coronavirus Vaccine Elicits a Robust Immune Response in Older Adults

Henrietta Brewer
November 20, 2020

The AstraZeneca/ Oxford vaccine is now in phase 3 trials, which are set to determine its efficacy. Therefore, assessment of immune responses with careful regard to this susceptible group is essential in the development of COVID-19 vaccines.

The vaccine produced fewer side-effects (like temporary fatigue) in the older age group, and blood samples proved it prompted a powerful immune response.

Now, researchers from the University of Oxford have released promising results from the phase II clinical trial of the vaccine candidate.

Trudeau's response comes after Ontario Health Minister Christine Elliott said on Wednesday that the province is expecting to get around 1.6 million doses of Pfizer's vaccine and around 800,000 of Moderna's for proper distribution by March 2021.


They found the Sinovac vaccine did create an antibody immune response, but at lower levels than those found in people who recovered from the coronavirus.

"Since elderly populations will be one of the priority groups to receive a vaccine when one is available, this is good news".

Study recruitment occurred during a national lockdown in the United Kingdom when vulnerable individuals were advised to self-isolate. The study, therefore, includes only healthy participants and not those with comorbidities. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.:17.

Professor Andrew Pollard, the vaccine group's director, said his team could release results by Christmas.


Scientists at the University of Oxford say their experimental COVID-19 vaccine shows a strong immune response among older people. "We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure".

The vaccination is done with two doses taken 14 days apart and the vaccine candidate is effective, which makes it suitable for emergency use amid the pandemic, said Zhu Fengcai, one of the authors of the findings.

"The robust antibody and T-cell responses seen in older people in our study are encouraging", said co-author Dr. Maheshi Ramasamy, also from Oxford.

China has been giving experimental Covid-19 vaccines to people including state employees, global students, and essential workers heading overseas since July.


Sources told ARY News that the health ministry sent a summary to the Economic Coordination Committee (ECC) in which it sought allocation of $150 million funds for advance booking of COVID-19 vaccines. "The next step will be to see if this translates into protection from the disease itself", he added.

Other reports by iNewsToday

FOLLOW OUR NEWSPAPER